© 2004 European Society for Medical Oncology; all rights reserved
Original Article |
CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients
Departments of 1 Pathology and 2 Medicine, Memorial Sloan-Kettering Cancer Center, NY; 3 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Center, New York, NY, USA
* Correspondence to: Dr J. Teruya-Feldstein, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel: +1-212-639-2130; Fax: +1-212-717-3203; Email: feldstej{at}mskcc.org
Background: Plasmablastic lymphoma (PBL) has been described as a rapidly progressive and almost invariably fatal CD20– VS38c+ diffuse large-cell lymphoma with plasmablastic features, almost exclusively involving the jaw and oral mucosa in HIV-positive patients.
Methods: From 2001 to 2003 we evaluated 12 men with PBL, and report the pathology, clinical findings, treatment and outcome. Six of 12 were HIV-positive while among the others, one was post-renal transplant, one had ulcerative colitis and four had no known immunodeficiency.
Results: Tumor growth pattern, in general, showed cohesiveness and a starry-sky pattern; the morphology varied from typical plasmablastic to centroblastic cells. Partial immunophenotypes were (+/total): CD138, 11 of 12 (91.7%); MIB1 10 of 11 (4+, range 75–95%); p63/VS38c, nine of 10 (90%); EBV, eight of 11 (73%); LCA(CD45), two of 12 (16.7%); HHV8/LANA, zero of 10; ALK, zero of seven; and CD20, zero of 12. Three had stage IE and nine stage IV disease. Nine of 12 had an intermediate/high International Prognostic Index or high-risk disease. Computed tomography and positron emission tomography scan in four of 12 revealed extensive bone metastases. Eight of 12 are alive after treatment, with a median follow-up of 11+ months (range 1–24). Of the HIV-positive patients, five of six are alive with a median follow-up of 17 months.
Conclusions: It appears that PBL are heterogenous in terms of clinical presentation and morphology. The outcome presented here is superior to that originally reported.
Key words: EBV-positive, HIV-positive/negative patients, plasmablastic lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H-J Delecluse, R Feederle, B O'Sullivan, and P Taniere Epstein Barr virus-associated tumours: an update for the attention of the working pathologist J. Clin. Pathol., December 1, 2007; 60(12): 1358 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Prakash and S. H Swerdlow Nodal aggressive B-cell lymphomas: a diagnostic approach J. Clin. Pathol., October 1, 2007; 60(10): 1076 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Redmond, J Quinn, P Murphy, S Patchett, and M Leader Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy J. Clin. Pathol., January 1, 2007; 60(1): 80 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Navarro and L. D. Kaplan AIDS-related lymphoproliferative disease Blood, January 1, 2006; 107(1): 13 - 20. [Abstract] [Full Text] [PDF]
|
|